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Histological diagnosis of renal osteodystrophy. Histology and Processing tissue for examination
histomorphometry are the two primary methods of using bone
For histomorphometry the biopsy must be sectionedbiopsies to diagnose renal osteodystrophy. However, appro-
“undecalcified,” a double negative indicating that this ispriate diagnoses can only be rendered when there is complete
not the usual way for bone to be prepared for micros-understanding of bone structure, of they way bone is processed
for histology, and of the manner in which analyses of samples copy. The tissue must be cut very thinly in order for
proceeds. In the future, modern applied molecular biology tech- light to pass through the slice or section, a necessity
niques will be added to these standards and redefine diagnoses. engendered by the workings of the light microscope. Cut
and unsupported, the bone would tear away from the
softer marrow, destroying the interface, which is the sin-
The pathologist has two tools with which to make gle most important area of the biopsy, as it is here that
histologic diagnoses on bone biopsies: subjective histo- most bone cells act. Thin sectioning is usually achieved
logic examination and histomorphometry. Before any- by embedding the biopsy in a polymerized plastic resin
one can meaningfully interpret data derived from histo- of a similar consistency to bone matrix. To adequately
logic examination, they must understand the way in infiltrate the biopsy with resin necessitates a number of
which these two tools are used, their shortcomings, and processing steps, during which the tissue is immersed in
their advantages [1, 2]. To understand both requires a series of chemicals, all of which have the effect of
knowledge of the bone itself, how it is treated during causing the biopsy to change size. Although this effect
processing for histologic analysis, and the way in which may be imperceptible to the naked eye, it causes alter-
subjective and objective data are derived from it. ations easily detected in the light microscope. These al-
terations have implications for histomorphometry, a
technique that relies on taking and comparing measure-THE BONE BIOPSY
ments. Size changes continue to occur during the later
The bone is obtained, preferably as a transiliac core stages of processing and sectioning.
using a specially designed trephine needle [3], and im-
mersed into fixative. The most commonly used fixative Technological problems affecting bone data
is alcohol, which preserves tissue by dehydration. Alco- Several other factors can affect the morphology of the
hol is used in preference to water-based cross-linking processed bone sample. Polymerization of the mono-
fixatives such as formaldehyde because of its ability to mer—which, by the end of processing, replaces all the
penetrate through fatty marrow to the bone surfaces water in the tissue—can, if uncontrolled, lead to a vigor-
where bone cells are found, as well as the absence in ous exothermic outcome with the potential to generate
alcohol of hydrogen ions, which might decalcify the tissue. sufficient heat to boil the tissue. Sectioning the tissue
The disadvantages of alcohol are that it is poor at using a mechanically-powered microtome inevitably pro-
preserving macromolecular epitopes and inhibiting nu- duces compressive loads on the tissue in one plane, re-
cleases, rendering it considerably inferior to other fixa- sulting in micro-distortion of the section. Staining the
tives for subsequent tissue probing by immunohisto- sections in water and/or alcohol-soluble dyes subjects
chemistry (IHC) or in situ hybridization (ISH). For this the tissue, or rather the resin in which it is embedded,
reason we split the biopsy into two longitudinally, pro- to physico-chemical forces (or, worse still, removes the
cessing one part specifically for ISH and IHC and the resin, which eliminates support and physical constraints).
other for morphometry. This has proved to be a very Mounting the section on a microscope slide and applying
useful strategy [4–8]. high loads to it “flattens” the section.
While these are technological problems, knowing that
they occur is important to the end-user who must make
clinical decisions based on the data obtained from analy- 1999 by the International Society of Nephrology
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sis of the sections. Fortunately, within any one laboratory
that holds to one protocol, the effects are relatively uni-
form and predictable, allowing valid comparison be-
tween data derived from different biopsies within that
laboratory. Much of histological diagnosis (including his-
tomorphometry) is comparative for just this reason, but
all diagnostic parameters are eventually compared with
“controls”; the best laboratories will have their own ade-
quate control populations processed in the same way as
their diagnostic biopsies [9].
DATA HELD WITHIN A BIOPSY
At the moment the fixative permeates the biopsy, all
Fig. 1. Transiliac bone biopsy. (a) Three-dimensional reconstructionmetabolic processes are suspended and the pathologist
of part of a transiliac bone biopsy using a high energy X-ray source. (b)is at his/her leisure to examine the snapshot of tissue Microscope section prepared from the biopsy. Toluidine blue staining,
events that were occurring within the tissue at that mo- magnification 1003.
ment. The main approach is to stain the tissue using tincto-
rial methods in such a way as to render components of
the tissue/cells distinguishable from one another [10, 11]. intervals, parallel lines of fluorescence can be seen sepa-
Interpretation is then based on distinctive morphology rated by unlabeled bone. The separation between the
and/or coloring of the important components of the tis- lines is a measure of the rate of mineralization and, in
sue. Interpretative features can be detected either by steady bone deposition states, the rate of bone forma-
eye or by trained machines. Thus, tinctorial staining dis- tion. From this simple expedient it is possible to take
tinguishes mineralized bone from osteoid, active cells the biopsy away from being a single snapshot in time
from relatively quiescent ones and sites of metal deposi- and turn it into a source of dynamic data.
tion from otherwise normal mineral [12, 13]. Morphology
distinguishes large multinucleated cells from mononu- Two-dimensional representations
clear ones and smooth from irregular bone surfaces. The microscope slide is effectively a two-dimensional
Many more data are held within the tissue than can representation of the tissue. This introduces a number
be visualized by simple staining and modern techniques, of complexities into interpretation. Most of these relate
applied to tissue sections, have enabled the cell and mo- to the fact that bone relies for its physical properties on
lecular biology of the bone to be investigated [14–16]. its three-dimensional structure; objective and subjective
This is where the techniques of ISH, IHC, etc. come in measurements must somehow reconcile the need to ex-
to their own. The advantage of these in situ techniques tend two-dimensional images into three-dimensional
over others is that molecules can be localized to specific functional units. This problem can be illustrated by ex-
cells, an essential when the tissue contains so many dispa- amining four aspects of bone biology:
rate cell types. As in situ techniques become more sophis- Trabecular connectivity. The strength of many bones
ticated [8], a greater amount of information can be ex- (e.g., vertebral bodies) depends upon the ability of tra-
tracted and interpretation of tissue events becomes more beculae to act as supporting rods. This property is a
precise. These methods will revolutionize the under- function of connectivity, a three-dimensional parameter
standing and treatment of bone disease. (Fig. 1a). The histopathologist sees the bone trabeculae
as two-dimensional structures (Fig. 1b). It is possible to
Tetracycline take series of two-dimensional sections and superimpose
One of the most important resources for interpreting them, mentally or using computerized reconstruction
events within bone is tetracycline labeling [17]. The tetra- programs, but it is never possible to exactly reproduce
cycline family of drugs has some very important and the structure in this way without time-consuming and
interesting properties. The drug is incorporated into min- complex geometrical reconstructions. Pathologists are
eralizing bone and other calcified tissues, and in ultravio- always looking for other ways to represent the three-
let light it fluoresces green to yellow (depending upon dimensional structure of bone. The image in Fig. 1a is
the exact molecular shape). If given to a patient prior generated by the high-energy X-ray emissions from a
to biopsy, it can be seen as a yellow-green line when synchrotron, a relatively nondestructive and time-effi-
unstained tissue sections are viewed in ultraviolet light. cient method for demonstrating connectivity. Unfortu-
This line can be used as a marker of mineralization. If nately, although Manchester University has an instru-
ment on-site, few laboratories have this level of access.two or more doses of tetracycline are given at specified
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Fig. 2. Two-dimensional representation of a circle (center) could be
part of a three-dimensional sphere (left) or a three-dimensional cylinder
(right).
Fig. 3. Diagram of 10 histologic sections through a piece of bone con-
taining an osteoclast. Sections 3–9 include the levels through the osteo-
clast. Serial sections 6–8 all contain the osteoclast, whereas in step serialSpheres and cylinders. This problem is illustrated by
sections 1 and 6 the osteoclast is only present in 6.
Figure 2. Simply put, the question is whether a circle
seen in two dimensions is part of a cylinder or a sphere.
At first sight this seems to be a very esoteric point, but
when two-dimensional images are converted to three- The thickness of the label is dependent upon the length
dimensional data (as recommended by the American of time over which the tetracycline is given. Many labora-
Society for Bone and Mineral Research [18]), the differ- tories request that each tetracycline label be given over
ences between spherical and cylindrical geometry intro- 3 or 4 days, giving relatively thick lines. Modern enhance-
duce the opportunity for considerable calculation errors. ment microscopy means that even small amounts of label
Such problems usually affect measurements of the cor- can be visualized. Consequently, we ask that patients
tex, so some laboratories do not routinely offer bone are given 15 mg of tetracycline per kilogram of body
cell or matrix measures for cortical bone. The majority weight over 12 hours, decreasing the artefact that comes
of bone tissue in the body is cortical, and many diseases from obliquely sectioned saucers of tetracycline [19].
(e.g., hyperparathyroidism) manifest most in the cortex.
SubjectivityAs a consequence, we offer cortical data and thus the
nature of the geometry of the cortical bone units is of No matter how careful the observer or complex the
particular importance. computer program, the nature of bone is such that sub-
Big cells. In reconstructing three-dimensional struc- jective measures will always influence interpretation of
tures, there is a temptation to use serial sections of bone. histologic sections of bone. For instance, all stains of
Some structures are larger than the section is thick. The osteoid will also stain non-mineralized fibrous tissue the
most notable example is the osteoclast. Osteoclasts are same color. In low-turnover bone states, osteoid seams
few in number and very large. A commonly used parame- may be very thin and approach the thickness (thinness)
ter in assessing bone is “osteoclast number,” derived by of the fibrous tissue that covers all resting bone surfaces.
counting osteoclast profiles in tissue sections and relating Assessing just what is osteoid and what is fibrous tissue
these to tissue volume or surface. If sections are selected can be very difficult under these circumstances, making
that are too close together (Fig. 3) the same osteoclast extent of osteoid surfaces a difficult parameter to define.
appears in several sections. While this would have no The same applies to distinguishing between osteoblasts
effect if one were measuring the volume of the tissue and obliquely sectioned resting surface cells. The most
occupied by osteoclast, when counting cells per unit area notoriously subjective area of bone histomorphometry
or length of bone surface it introduces a multiplication is assessment of resorptive surfaces, which despite many
area that could lead to misinterpretation, e.g., mistaking attempts has yet to be successfully automated. Some
normal bone for bone in a high turnover state such as choose to use surface irregularity (in the absence of an
hyperparathyroidism. For this reason we perform histo- osteoid surface) as the criterion, while others use erosion
morphometry on “step serial” sections, i.e., sections through collagen lamellae assessed in polarized light
taken every 40–50 mm. (Fig. 5.). There is no universal agreement as to how this
Lines or saucers. In biopsies, thin structures such as parameter should be derived.
tetracycline labels appear as lines (Fig. 4), and it is tempt-
Controlsing to think of them as being effectively one-dimensional.
Tetracycline labels are not lines but are very thin, saucer- The subject of controls has been alluded to already.
Differential shape change induced by processing andshaped deposits incorporated into bone by a sheet of
osteoblasts. If the sectioning is not tangential to the edge sectioning will affect the size and shape of tissue section
profiles, and this has influenced our decision to have “in-of the saucer, the line of the tetracycline is not sharp
but is thickened and indistinct. Clearly, the thinner the house” controls [9]. There is considerable variation in
bone parameters in “normal” individuals with sex andtetracycline label, the less of a problem this becomes.
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Fig. 4. Unstained histological section viewed in UV light. The tetracy- Fig. 5. Section of bone viewed in polarized light to show one way of
identifying resorption surfaces. (Original magnification 3250).cline appears bright. Various artefacts caused by sectioning are seen
in the biopsy, including effects due to oblique sectioning. (Original
magnification 3200).
quence of disturbed bone cell function. Effectively, there
are 4 bone cells: osteoblast, osteoclast, resting surfaceage and so our normal values cover a wide range of ages
cell and osteocyte. If adequate technology existed, itand both sexes in 10 years cohorts. Even these data are
would be possible to define all bone diseases in termslimited as they only pertain to biopsies from the anterior
of the function of these four cell types. Despite introduc-iliac crest of Caucasians. Other bones, other sites in the
ing in situ molecular techniques (IHC, ISH) into ouriliac bone, and other ethnic groups will have different
diagnostic armory, we are only scratching at the surfacemeasures.
of understanding bone cell function and interactions.The generation and interpretation of biopsies is there-
However, it is entirely possible to redefine bone diseasefore subjective, complex and unusually observer depen-
in terms of the number and function of osteoblasts anddent. It can be overcome by using a laboratory with long-
osteoclasts based on current histomorphometric data.standing standardized technology, in-house controls and,
The only problem we find is selecting which parametersunusually for scientific studies, only one data generator.
to use to define these 4 measures from among the 32This is not, however, the only problem confronting the
parameters we give to clinicians on every biopsy and thepathologist.
21 that we measure or derive but don’t release withThis laboratory receives between 100 and 150 bone
each report. However, all the data indicate that with thebiopsies from renal patients from 8 countries each year,
development of further pharmaceutical and alternativeand has done so for more than 30 years. It is becoming
therapeutic strategies, it might soon be possible to influ-apparent that renal bone disease is changing with time
ence the behavior and/or number of individual cell types.[20, 21]. For example, adynamic bone was not a feature
The prospect that biopsy-derived data could be the basisof our practice until 1985, yet it now accounts for 40%
for treatment tailored to the needs of individual patientsor more of the biopsies received [22–24]. In a similar
is an exciting challenge and opportunity.vein, renal bone disease is different in different dialysis
and transplantation centers around the world. While typ-
ical hyperparathyroid bone disease is seen in Mexico
FUTURE POSSIBILITIESand Greece, it is seen increasingly rarely in England
If the trends we are seeing are recognized in otheror Sweden; in the latter two countries, peritrabecular
countries, the need we have encountered to redefinemarrow fibrosis and increased osteoclasis, hallmarks of
bone disease in terms of differential cell function/numberhyperparathyroid bone disease, are increasingly associ-
will lead to a reclassification of bone disease. This willated with relatively poor osteoblast function, perhaps be-
be facilitated by modern laboratory techniques that en-cause of resistance to parathyroid hormone [23, 25, 26].
able the molecular biology of bone disease to be exploredIt is becoming increasingly difficult to “shoe horn”
in tissue, and hence within single cell types in their natu-patients into typical disease categories, e.g., adynamic
ral physical and chemical environment. This holds outbone, hyperparathyroid bone disease, osteomalacia. Be-
considerable hope for new, highly-targeted therapies forcause of these problems, we have adopted a different
the management of bone disease in patients with renalapproach towards the analysis of bone biopsies in pa-
tients with renal dysfunction. All bone disease is a conse- dysfunction.
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